BIO in the 13F filings
Bio Rad Labs Inc · CUSIP 090572207
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 26
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 7 listed it in both
- Shares listed
- 4,820,889
- combined, among listed positions
- Reported value
- $1.3bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 18 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +480,790.
Managers listing BIO in Q1 2026
26 of 26 holders
Largest increases and reductions, by shares
Increases
- Capital World Investorsnew position · 450,000 shares now+450,000
- Citadel Advisors LLCexisting position · 148,669 shares now+139,189
- Man Group PLCexisting position · 67,436 shares now+61,185
- AQR Capital Management LLCexisting position · 94,549 shares now+54,354
- Freestone Grove Partners LPexisting position · 147,605 shares now+37,081
Reductions
- Capital Research Global Investorsexisting position · 385,579 shares now-108,893
- Southeastern Asset Management Incexisting position · 162,804 shares now-64,826
- Millennium Management LLCexisting position · 3,294 shares now-18,912
- Acadian Asset Management LLCexisting position · 102,800 shares now-17,834
- MFS Investment Managementexisting position · 396,150 shares now-3,057
New positions and exits
New (7)
Exited (8)
- Jane Street Group LLCwas $22m
- Moore Capital Management LPwas $15m
- Quantbot Technologies LPwas $1.8m
- Squarepoint Ops LLCwas $1.6m
- ExodusPoint Capital Management LPwas $1.3m
- Verition Fund Management LLCwas $1.2m
- Schonfeld Strategic Advisors LLCwas $597k
- Caxton Associates LLPwas $444k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 5 | $24m | n.a. | n.a. |
| Q3 2013 | 4 | $22m | n.a. | n.a. |
| Q4 2013 | 2 | $13m | n.a. | n.a. |
| Q1 2014 | 3 | $34m | n.a. | n.a. |
| Q2 2014 | 4 | $33m | n.a. | n.a. |
| Q3 2014 | 5 | $22m | n.a. | n.a. |
| Q4 2014 | 5 | $41m | n.a. | n.a. |
| Q1 2015 | 8 | $145m | n.a. | n.a. |
| Q2 2015 | 6 | $170m | n.a. | n.a. |
| Q3 2015 | 7 | $201m | n.a. | n.a. |
| Q4 2015 | 7 | $186m | n.a. | n.a. |
| Q1 2016 | 6 | $182m | n.a. | n.a. |
| Q2 2016 | 4 | $188m | n.a. | n.a. |
| Q3 2016 | 4 | $224m | n.a. | n.a. |
| Q4 2016 | 7 | $317m | n.a. | n.a. |
| Q1 2017 | 9 | $340m | n.a. | n.a. |
| Q2 2017 | 8 | $298m | n.a. | n.a. |
| Q3 2017 | 4 | $294m | n.a. | n.a. |
| Q4 2017 | 13 | $478m | n.a. | n.a. |
| Q1 2018 | 13 | $524m | n.a. | n.a. |
| Q2 2018 | 15 | $657m | n.a. | n.a. |
| Q3 2018 | 16 | $686m | n.a. | n.a. |
| Q4 2018 | 16 | $498m | n.a. | n.a. |
| Q1 2019 | 15 | $689m | n.a. | n.a. |
| Q2 2019 | 14 | $614m | n.a. | n.a. |
| Q3 2019 | 16 | $801m | n.a. | n.a. |
| Q4 2019 | 12 | $585m | n.a. | n.a. |
| Q1 2020 | 12 | $695m | n.a. | n.a. |
| Q2 2020 | 19 | $1.3bn | n.a. | n.a. |
| Q3 2020 | 17 | $1.7bn | n.a. | n.a. |
| Q4 2020 | 13 | $2.2bn | n.a. | n.a. |
| Q1 2021 | 15 | $2.2bn | n.a. | n.a. |
| Q2 2021 | 18 | $2.7bn | n.a. | n.a. |
| Q3 2021 | 16 | $3.5bn | n.a. | n.a. |
| Q4 2021 | 19 | $3.3bn | n.a. | n.a. |
| Q1 2022 | 22 | $2.4bn | n.a. | n.a. |
| Q2 2022 | 15 | $1.2bn | n.a. | n.a. |
| Q3 2022 | 17 | $857m | n.a. | n.a. |
| Q4 2022 | 16 | $782m | n.a. | n.a. |
| Q1 2023 | 11 | $833m | n.a. | n.a. |
| Q2 2023 | 16 | $607m | n.a. | n.a. |
| Q3 2023 | 15 | $662m | n.a. | n.a. |
| Q4 2023 | 11 | $534m | 8 | 5 |
| Q1 2024 | 7 | $342m | 4 | 6 |
| Q2 2024 | 6 | $409m | 3 | 2 |
| Q3 2024 | 9 | $708m | 7 | 1 |
| Q4 2024 | 11 | $649m | 5 | 4 |
| Q1 2025 | 10 | $612m | 6 | 3 |
| Q2 2025 | 8 | $780m | 4 | 3 |
| Q3 2025 | 8 | $983m | 4 | 3 |
| Q4 2025 | 9 | $1.2bn | 12 | 21 |
| Q1 2026 | 8 | $1.2bn | 18 | 14 |
| Q2 2026 | 7 | $1.1bn | 15 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BIO and LLY →BIO and JNJ →BIO and VRTX →Choose a stock to compare with BIO →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BIO, latest filings →Back to the 13F Explorer →